In lat­est set­back for stem cell sec­tor, Celyad fails PhI­II— and the biotech claims a vic­to­ry

At first glance, the idea that stem cells can be used to strength­en a dam­aged heart has a po­tent at­trac­tion. It sounds sen­si­ble enough in the panoply of re­gen­er­a­tive med­i­cine. But Celyad’s pro­gram to prove that it has the right ap­proach with Cure-C just failed in Phase III, of­fer­ing a new set­back to a trou­bled field and a body blow to the biotech com­pa­ny.

For Celyad’s ($CYAD) part, the fact that the Phase III failed was dis­pensed with quick­ly so the com­pa­ny could im­me­di­ate­ly move on to its an­a­lyt­i­cal break­down, point­ing to a sig­nif­i­cant sub­pop­u­la­tion of pa­tients the com­pa­ny in­sists were helped by C-Cure. That analy­sis is giv­ing them grounds to ap­proach the EMA on fil­ing the drug while flag­ging their ea­ger­ness to do a deal on the project, look­ing for an­oth­er com­pa­ny to fund de­vel­op­ment and back a com­mer­cial­iza­tion move.

That will be a hard ar­gu­ment to make with in­vestors. Heart dis­ease in spe­cif­ic – which af­fects mil­lions of peo­ple – is one of the most de­mand­ing fields in R&D, with a very high bar for prov­ing ef­fi­ca­cy and safe­ty to reg­u­la­tors. And in­vestors ini­tial re­sponse was to flee, send­ing Celyad’s shares down about 40% this morn­ing.

When you want to dress up a Phase III fail­ure, the first thing you point to is a “pos­i­tive trend” across the pa­tients treat­ed. Celyad didn’t miss that point. In­ves­ti­ga­tors then ze­roed in on a group of pa­tients “cat­e­go­rized by their End Di­as­tolic Vol­ume (EDV) at in­clu­sion, sig­nif­i­cance was met for the pri­ma­ry end­point (p = 0.015). Most im­por­tant­ly, in this sub­group, a strong trend or a sta­tis­ti­cal sig­nif­i­cant pos­i­tive dif­fer­ence was seen in all in­di­vid­ual el­e­ments of the com­pos­ite pri­ma­ry end­point (Mor­tal­i­ty, Wors­en­ing Heart Fail­ure Events, Qual­i­ty of Life, 6 min­utes Walk­ing Test, End Sys­tolic Vol­ume and Ejec­tion Frac­tion).”

There was no break­down on which the­o­ret­i­cal end­points were hit by the sub­pop­u­la­tion.

Phase III stud­ies, though, aren’t de­signed to iden­ti­fy pa­tient pop­u­la­tions. They’re in­tend­ed to pro­vide con­clu­sive ev­i­dence that a treat­ment is ei­ther ef­fec­tive or safe, or it isn’t.

The Phase III fail­ure fol­lows a de­ci­sion by Te­va just days ago to with­draw from its stem cell pact with Mesoblast, which bad­ly dam­aged the biotech’s share price. And days be­fore that Bio­Car­dia was forced to pull its $50 mil­lion IPO – de­signed to back its own late-stage stem cell treat­ment for heart dis­ease – af­ter it failed to gain enough sup­port for the move.

Celyad – which changed its name in an ef­fort to high­light a new fo­cus on the trendy CAR-T field – sus­pend­ed trad­ing for its shares un­til af­ter a morn­ing press con­fer­ence.

Hal Barron, GSK

Break­ing the death spi­ral: Hal Bar­ron talks about trans­form­ing the mori­bund R&D cul­ture at GSK in a crit­i­cal year for the late-stage pipeline

Just ahead of GlaxoSmithKline’s Q2 update on Wednesday, science chief Hal Barron is making the rounds to talk up the pharma giant’s late-stage strategy as the top execs continue to woo back a deeply skeptical investor group while pushing through a whole new R&D culture.

And that’s not easy, Barron is quick to note. He told the Financial Times:

I think that culture, to some extent, is as hard, in fact even harder, than doing the science.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.

Aca­dia is mak­ing the best of it, but their lat­est PhI­II Nu­plazid study is a bust

Acadia’s late-stage program to widen the commercial prospects for Nuplazid has hit a wall. The biotech reported that their Phase III ENHANCE trial flat failed. And while they $ACAD did their best to cherry pick positive data wherever they can be found, this is a clear setback for the biotech.

With close to 400 patients enrolled, researchers said the drug flunked the primary endpoint as an adjunctive therapy for patients with an inadequate response to antipsychotic therapy. The p-value was an ugly 0.0940 on the Positive and Negative Syndrome Scale, which the company called out as a positive trend.

Their shares slid 12% on the news, good for a $426 million hit on a $3.7 billion market cap at close.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.

Some Big Phar­mas stepped up their game on da­ta trans­paren­cy — but which flunked the test?

The nonprofit Bioethics International has come out with their latest scorecard on data transparency among the big biopharmas in the industry — flagging a few standouts while spotlighting some laggards who are continuing to underperform.

Now in its third year, the nonprofit created a new set of standards with Yale School of Medicine and Stanford Law School to evaluate the track record on trial registration, results reporting, publication and data-sharing practice.

Busy Gilead crew throws strug­gling biotech a life­line, with some cash up­front and hun­dreds of mil­lions in biobucks for HIV deal

Durect $DRRX got a badly needed shot in the arm Monday morning as Gilead’s busy BD team lined up access to its extended-release platform tech for HIV and hepatitis B.

Gilead, a leader in the HIV sector, is paying a modest $25 million in cash for the right to jump on the platform at Durect, which has been using its technology to come up with an extended-release version of bupivacaine. The FDA rejected that in 2014, but Durect has been working on a comeback.

In­tec blitzed by PhI­II flop as lead pro­gram fails to beat Mer­ck­'s stan­dard com­bo for Parkin­son’s

Intec Pharma’s $NTEC lead drug slammed into a brick wall Monday morning. The small-cap Israeli biotech reported that its lead program — coming off a platform designed to produce a safer, more effective oral drug for Parkinson’s — failed the Phase III at the primary endpoint.

Researchers at Intec, which has already seen its share price collapse over the past few months, says that its Accordion Pill-Carbidopa/Levodopa failed to prove superior to Sinemet in reducing daily ‘off’ time. 

Cel­gene racks up third Ote­zla ap­proval, heat­ing up talks about who Bris­tol-My­ers will sell to

Whoever is taking Otezla off Bristol-Myers Squibb’s hands will have one more revenue stream to boast.

The drug — a rising star in Celgene’s pipeline that generated global sales of $1.6 billion last year — is now OK’d to treat oral ulcers associated with Behçet’s disease, a common symptom for a rare inflammatory disorder. This marks the third FDA approval for the PDE4 inhibitor since 2014, when it was greenlighted for plaque psoriasis and psoriatic arthritis.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.

Francesco De Rubertis

Medicxi is rolling out its biggest fund ever to back Eu­rope's top 'sci­en­tists with strange ideas'

Francesco De Rubertis built Medicxi to be the kind of biotech venture player he would have liked to have known back when he was a full time scientist.

“When I was a scientist 20 years ago I would have loved Medicxi,’ the co-founder tells me. It’s the kind of place run by and for investigators, what the Medicxi partner calls “scientists with strange ideas — a platform for the drug hunter and scientific entrepreneur. That’s what I wanted when I was a scientist.”

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.

Af­ter a decade, Vi­iV CSO John Pot­tage says it's time to step down — and he's hand­ing the job to long­time col­league Kim Smith

ViiV Healthcare has always been something unique in the global drug industry.

Owned by GlaxoSmithKline and Pfizer — with GSK in the lead as majority owner — it was created 10 years ago in a time of deep turmoil for the field as something independent of the pharma giants, but with access to lots of infrastructural support on demand. While R&D at the mother ship inside GSK was souring, a razor-focused ViiV provided a rare bright spot, challenging Gilead on a lucrative front in delivering new combinations that require fewer therapies with a more easily tolerated regimen.

They kept a massive number of people alive who would otherwise have been facing a death sentence. And they made money.

And throughout, John Pottage has been the chief scientific and chief medical officer.

Until now.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.

Vlad Coric (Biohaven)

In an­oth­er dis­ap­point­ment for in­vestors, FDA slaps down Bio­haven’s re­vised ver­sion of an old ALS drug

Biohaven is at risk of making a habit of disappointing its investors.

Late Friday the biotech $BHVN reported that the FDA had rejected its application for riluzole, an old drug that they had made over into a sublingual formulation that dissolves under the tongue. According to Biohaven, the FDA had a problem with the active ingredient used in a bioequivalence study back in 2017, which they got from the Canadian drugmaker Apotex.

Apotex, though, has been a disaster ground. The manufacturer voluntarily yanked the ANDAs on 31 drugs — in late 2017 — after the FDA came across serious manufacturing deficiencies at their plants in India. A few days ago, the FDA made it official.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.